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Abstract
CFTR is a dynamically regulated anion channel. Intracellular WNK1-SPAK activation causes CFTR to change permeability and
conductance characteristics from a chloride-preferring to bicarbonate-preferring channel through unknown mechanisms.
Two severe CFTR mutations (CFTRsev) cause complete loss of CFTR function and result in cystic fibrosis (CF), a severe genetic
disorder affecting sweat glands, nasal sinuses, lungs, pancreas, liver, intestines, and male reproductive system. We
hypothesize that those CFTR mutations that disrupt the WNK1-SPAK activation mechanisms cause a selective, bicarbonate
defect in channel function (CFTRBD) affecting organs that utilize CFTR for bicarbonate secretion (e.g. the pancreas, nasal
sinus, vas deferens) but do not cause typical CF. To understand the structural and functional requirements of the CFTR
bicarbonate-preferring channel, we (a) screened 984 well-phenotyped pancreatitis cases for candidate CFTRBD mutations
from among 81 previously described CFTR variants; (b) conducted electrophysiology studies on clones of variants found in
pancreatitis but not CF; (c) computationally constructed a new, complete structural model of CFTR for molecular dynamics
simulation of wild-type and mutant variants; and (d) tested the newly defined CFTRBD variants for disease in non-pancreas
organs utilizing CFTR for bicarbonate secretion. Nine variants (CFTR R74Q, R75Q, R117H, R170H, L967S, L997F, D1152H,
S1235R, and D1270N) not associated with typical CF were associated with pancreatitis (OR 1.5, p = 0.002). Clones expressed
in HEK 293T cells had normal chloride but not bicarbonate permeability and conductance with WNK1-SPAK activation.
Molecular dynamics simulations suggest physical restriction of the CFTR channel and altered dynamic channel regulation.
Comparing pancreatitis patients and controls, CFTRBD increased risk for rhinosinusitis (OR 2.3, p,0.005) and male infertility
(OR 395, p,,0.0001). WNK1-SPAK pathway-activated increases in CFTR bicarbonate permeability are altered by CFTRBD
variants through multiple mechanisms. CFTRBD variants are associated with clinically significant disorders of the pancreas,
sinuses, and male reproductive system.
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Introduction
The cystic fibrosis transmembrane conductance regulator
(CFTR, GenBank Accession: AH006034.1) is an ATP-binding
cassette (ABC) transporter-type protein localized to the apical
plasma membrane of epithelial cells. It differs from other ABC
transporters in that it acts as a regulated anion channel rather than
a transporter [1]. When the channel is open, anions move across
the membrane down their electrochemical potential gradient,
resulting in fluid and electrolyte secretion or absorption.
The CFTR molecule has been intensely studied because
mutations in the CFTR gene are associated with cystic fibrosis
(CF, OMIM #219700), the most common life-threatening genetic
disorder among populations of Northern European ancestry[2,3].
However, the clinical features of CF and CFTR-related disorders
are variable, and laboratory studies of CFTR regulation, its
biophysical properties and molecular mechanisms of (dys)function
have been challenging due to the complexity of the regulatory
mechanisms and the dynamic flexibility of various structural
domains (see recent reviews [4,5]).
Cystic fibrosis is an autosomal recessive syndrome usually
caused by inheriting two CFTR mutations that eliminate effective
chloride conductance (CFTRCF)[2,3]. Although nearly 2000
CFTR variants have been described (http://www.genet.sickkids.
on.ca), the majority of CF cases are associated the CFTR 508F-del
mutation as a homozygous genotype or in combination with
another severe CF-associated mutation (CFTRCF/CFTRCF) that
together result in minimal CFTR function. Thus, most research
has focused on the regulation of chloride conductance, and
dynamic modeling of the first of two nucleotide-binding domains
(NBD1), which normally contains F508 [4,5]. Based on numerous
studies, three conformations have been described for the molecule
as an anion channel: a closed state, an open state, and an open-
ready state [4]. However, the relative permeability/conductance
ratios of chloride and bicarbonate are variable [6] and may be
dynamically regulated [7], suggesting that conformational changes
induced by point mutations in the channel or in the permeability
pore may alter ion permeation properties of CFTR.
Diagnosis of CF is based on a combination of phenotypic
features, family history, functional tests and/or the identification
CFTRCF variants on both alleles[8,9]. Organ dysfunctions begin
in utero and include chronic pancreatitis, meconium ileus, and
congenital bilateral agenesis of the vas deferens. Progressive
sinorespiratory dysfunction develops in childhood due to bacterial
infections, inflammation, and scarring, and male infertility is
recognized in adulthood. Disease severity and complexity is
modified by other genes[10–12], environmental factors[13], and
mild-variable CFTR variants [3,14]. Mild CF phenotypes, CFTR-
related disorders limited to a single organ, are associated with non-
CFTRCF variants with residual channel function, classified as
mild-variable variants (CFTRm-v) [2,9,15].
CFTRsev and CFTRm-v variants are associated with recurrent
acute pancreatitis and chronic pancreatitis [16–19]. Recently, we
reported that the variant CFTR R75Q, which was previously
classified as benign, is associated with familial and sporadic
chronic pancreatitis, either with another CFTR variant (recessive)
or with the serine protease inhibitor, Kazal Type 1 (SPINK1)
N34S high-risk haplotype (complex genotype)[18]. Patch-clamp
studies of CFTR R75Q clones under standard conditions
demonstrated normal chloride conductance but a selective
disruption in bicarbonate conductance[18]. Thus, CFTR R75Q
causes selective bicarbonate defective (CFTRBD) conductance and
is associated with chronic pancreatitis but not CF[18]. It is not
known if other CFTR variants share this phenotypic feature,
whether the defect is associated with the channel function under
all or special conditions, or if other mechanism(s) underlying these
observation.
Independently, we demonstrated that CFTR bicarbonate
(HCO3
2) permeability increases through WNK1-SPAK signaling
pathway activation [20]. WNK1 is member of the ‘‘with-no-K’’
(Lys) kinases that serves as a sensor of osmolality, chloride
concentration, and other factors within cells and respond by
activating additional kinases linked to a variety of ion channels and
exchanges, including CFTR [20–22]. In cell-based models, low
intracellular chloride concentrations ([Cl2]i) result in WNK1-
mediated SPAK activation that strongly increases CFTR HCO3
2
permeability in CFTR-transfected HEK 293T, PANC1, and
guinea pig pancreatic duct cells, making CFTR primarily an
HCO3
2 channel [20]. The structural and dynamic mechanisms of
this phenomenon are unknown.
We hypothesized that CFTR variants that disrupt the WNK1-
SPAK-associated increase in bicarbonate permeability will in-
crease the risk of pancreatitis and affect other organs in which
CFTR is used for bicarbonate secretion. To test this hypothesis
and to gain insight into potential mechanisms, we adopted a
multidisciplinary approach. First, to identify candidate CFTRBD
variants, we conducted a systematic review of the literature to
compile CFTR variants that have been reported at least twice in
previous chronic pancreatitis case-control genetic studies, plus
common CFTRCF variants. Second, using this panel of 81 CFTR
variants (Table S1 in the Supplementary Material), we genotyped
the deeply phenotyped North American Pancreatitis Study 2
(NAPS2) subjects[23] to identify candidate CFTRBD variants that
were also present in our cases and controls (43 of them, listed in
Table 1). Third, to determine if CFTRBD variants are associated
with altered WNK1-SPAK pathway-stimulated CFTR bicarbon-
ate permeability, we generated plasmids containing the candidate
CFTRBD variants selected from the NAPS2 study and expressed
them in HEK-293T cells for electrophysiological analysis. Fourth,
to gain insight into the molecular mechanisms of CFTRBD
dysfunction, we performed molecular dynamics (MD) simulations
based on homology-modeled structures of ABC transporters and
examined the effect of CFTRBD variants on the structure and
dynamics of the channel. Finally, to determine if CFTRBD variants
are associated with disease in non-pancreatic tissues, we used the
phenotyping criteria for sinusitis and male infertility for the
NAPS2 cases and controls.
These studies revealed at least 9 CFTRBD variants. We found
that the WNK1-SPAK pathway that enhances CFTR bicarbonate
permeability/conductance compared with chloride conductance
in HEK-293T cells is altered by CFTRBD variants. The
examination of MD trajectories suggests at least two potential
mechanisms of channel dysfunction. Phenotype-genotype studies
CFTR Bicarbonate Permeation Variants
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in humans demonstrated that CFTRBD variants are also associated
with disorders of the pancreas, sinuses, and male reproductive
systems.
Results
CFTR genotyping in pancreatitis patients and controls
We genotyped 984 well-phenotyped cases of pancreatitis from
NAPS2 for 81 CFTR variants, including common CF mutations
and variants previously reported in at least two subjects with
pancreatitis but not CF. Common tag-SNPs at the CFTR locus
were previously excluded in a pancreatitis genome-wide associa-
tion study (all p values $0.01) [24], suggesting that the missing
heritability and predicted dysfunction was primarily associated
with multiple rare variants. SPINK1 N34S was also genotyped to
determine complex risk [18]. Only SPINK1 N34S heterozygotes
were used for trans-heterozygote analysis with CFTR, since
homozygous SPINK1 N34S is sufficient to cause pancreatitis.
Of 43 CFTR variants identified in the NAPS2 cohort (Table 1),
nine not associated with typical CF but reported in patients with
pancreatitis[25–29] were of particular interest: R74Q, R75Q,
R117H (CFTRm-v only when in cis with IVS8-T5[30];
R117H*T5), R170H, L967S, L997F, D1152H, S1235R, and
D1270N. These were either independently associated with disease,
were found in subjects with SPINK1 N34S as a complex high-risk
trans-heterozygous genotype or had predicted clinical relevance
based on prior reports or their location on the CFTR molecule.
Taken together, these nine CFTRBD variants were found more
commonly in cases (14.2%) than controls (9.8%) (OR 1.5,
p = 0.002) (Table 1).
As expected, CFTR variants associated with typical CF were
also identified in more cases than controls (8.7% cases, 3.3%
controls; OR 2.8, p,0.0001). Other candidate CFTR variants,
including I148T, M470V, T854T, Q1463Q and the ‘‘5T’’ allele,
were either rare or were not associated with pancreatitis in our
cohort (Table 1). A total of 189 cases (19.8%) carried one or more
CFTR variants of any kind (controls 13.0%, p,0.0001, OR 1.6,
95% C.I 1.3–2.0): 38% of these mutations were CFTRCF variants,
while the remaining were CFTRBD variants (62%). Twenty-five
cases and no controls carried multiple mutations in CFTR.
Twenty-five cases carried trans-heterozygous mutations in both
CFTR and SPINK1 (N34S), including five patients with three or
more mutations (Table 2).
Several candidates that were previously reported to be
associated with pancreatitis or atypical CF were not replicated in
the NAPS2 cohort. I148T was seen in three cases and one control,
so an effect could not be detected or excluded; the in cis deletion
mutation 3199del6 was not detected in any I148T carriers. The
IVS8T5 variant was identified in 9.9% of cases and 8.2% of
controls, which is not individually significant. There were six
N34S/T5 trans-heterozygote controls and no cases, but the
combined effect of the SPINK1 N34S variant with IVS8T5 was
not significantly higher than N34S alone. Four variants were
identified in only one patient and no controls: CF mutations
2184delA, 3120+1G.A, R1162X, and mutation of varying
clinical consequence, G1069R.
Functional assays on CFTR variants
For our functional studies, we cloned the nine CFTR variants
and confirmed that they had normal folding, glycosylation
(Figure 1a) and chloride channel activities, except for R117H
(Figure 1b). Because CFTR bicarbonate permeability is dynam-
ically increased through [Cl2]i-sensitive WNK1-SPAK signaling
pathway activation[20], we tested this in HEK 293T cells[20]
using whole-cell current measurements by replacing 150 mM
extracellular Cl2 with 140 mM HCO3
2 and 10 mM Cl2.
Representative traces for voltage and current measurements are
presented in Figures 1c, 1d, and S2, and a summary of the
indicated numbers of experiments is depicted in Figure 1e and f.
The bicarbonate permeability of CFTR in cells that do not
overexpress WNK1 and SPAK was much smaller than that of
chloride, with PHCO3/PCl = 0.2460.05 (Figure S1). As reported
previously [20], with WNK1 and SPAK co-expression and low
[Cl2]i, the permeability of CFTR to bicarbonate increased and
reached that of chloride, with PHCO3/PCl = 1.0660.06 (Figure 1c
and 1e). In contrast, CFTR PHCO3/PCl failed to increase in
CFTR R170H (Figure 1d) and all of the candidate CFTRBD
variants (Figures 1e and S2). Furthermore, all CFTRBD
candidate variants lowered bicarbonate conductance (GHCO3/
GCl), which is an important metric determining apical bicarbonate
efflux in CFTR-expressing epithelia (Figure 1f); the decrease was
statistically significant for all variants except D1270N. Treatment
with the CFTR inhibitor CFTRinh-172 (20 mM) inhibited .90%
of the HCO3
2 currents (Figure S2), indicating that CFTR
mediates most of the HCO3
2 currents observed in the present
experiments.
To further evaluate the mechanism of bicarbonate conductance,
we tested the hypothesis that the well-established CFTR channel
blocker, CFTRinh—172[31–33] blocks HCO3
2 current. We found
that CFTRinh-172 (20 mM) inhibited .90% of the HCO3
2
currents (Figure S2), indicating that with WNK1-SPAK activation,
CFTR mediates most of the HCO3
2 currents.
Structural and dynamic modeling of CFTR wild-type and
variants
The specific amino acid substitutions that interfere with
WNK1/SPAK-activated transformation of CFTR to a more
efficient bicarbonate-conducting channel are scattered throughout
the linear DNA sequence, suggesting that three-dimensional
structure and/or mechanisms of dynamic conformational changes
linked to these amino acids are important risk for pancreatitis. We
Author Summary
Genetic disorders of ion channels can affect the body’s
ability to function properly in many ways. CFTR, an ion
channel regulating movement of chloride and bicarbonate
across cell membranes, is important for absorbing and
secreting fluids. If the gene responsible for the CFTR
channel is mutated severely, the result is cystic fibrosis, a
hereditary disorder in which the patient develops thick
mucus, especially in the lungs, as well as scarring (fibrosis)
in the pancreas. Cystic fibrosis also affects the sweat
glands, nasal sinuses, intestines, liver, and male reproduc-
tive system. Mutations to the CFTR gene that do not cause
cystic fibrosis have been considered benign. However, we
discovered 9 CFTR mutations that do not cause cystic
fibrosis but do cause inflammation and scarring of the
pancreas (chronic pancreatitis). These mutant CFTR chan-
nels secrete chloride, which is important in the sweat
glands, lungs, and intestines, but not bicarbonate, which is
important in the pancreas, sinuses, and male reproductive
tract. We found patients with any of these 9 mutations had
chronic pancreatitis, and often sinus infections, and male
infertility, but not other symptoms of cystic fibrosis. Our
computer models and data will help researchers develop
better drugs and help physicians treating patients with
chronic pancreatitis.
CFTR Bicarbonate Permeation Variants
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computationally modeled the molecular structure, and studied
the dynamics, of wild type (WT) and mutated CFTR channels.
Because the effective van der Waals radius of chloride (1.8 A˚
[34]) is smaller than that of bicarbonate (2.6 A˚, see Methods), we
tested whether amino acid substitutions that reduced the inner
diameter of the CFTR channel could selectively impede
bicarbonate conductance. A CFTR-WT model (Figure 2a)
was constructed [35,36] and used to locate and study CFTRBD
functional variants (Figure 1). The model is based on the most
recently resolved ABC transporter structure (from Staphylococcus
aureus sav1866; see Materials and Methods). Figure S3 a shows
the superposition of our model on this crystal structure, which
yields an RMSD of 1.6 A˚. Panel b shows that residues lining the
pore at the membrane-spanning domain (MSD), observed by the
end of 50 ns simulations, agree in general with the CFTR model
built by Norimatsu and collaborators [37,38] which was also
confirmed by cysteine scanning experiments [37,39]. Likewise,
the pore radius profile evaluated for our wild-type structural
model (Figure S3 c solid curve, with the gray band displaying
the fluctuations observed in 50 ns simulations) is qualitatively
consistent with that observed by Norimatsu and coworkers [37]
for the MSD.
MD simulations comparing the channel diameters of the WT
and mutants L997F and D1152H (Figure 2c–f) demonstrate
that the channel diameter is observed to narrow down from an
average value of 10.3 A˚ to 7.5 A˚ (standard deviation, s= 0.5 A˚)
at the pore region, near the L997F amino acid substitution
(Figure 2e), and from an average of 9.9 A˚ to 4.3 A˚ (s= 1.1 A˚)
for the CFTRBD mutant D1152H (Figure 2f). Note that in
contrast to the WT CFTR and L997F mutant where the
structure maintains its stability, the D1152H mutation induces
significant fluctuations in local conformation, which are reflected
on the changes in the pore diameter at this location within the
channel.
In order to determine residues that play a key role in the global
dynamics of the CFTR, we performed an elastic network model
(ENM) analysis. ENM analysis provides information on the
mechanisms of collective movements intrinsically accessible to the
structure, which usually enable structural changes relevant to
function [40]. Application to CFTR highlighted the critical
positioning of R74, R75, R170, L967, and R1162 at the hinge
region that modulates the collective movements of the nucleotide-
binding domains (NBDs) with respect to membrane-spanning
domains (MSDs) (mode 1 in Figure 3). We also note that
L967, L997, D1152, and R1162 act as anchors in collective mode
2. In this mode, the two NBDs are observed to move in opposite
directions (see color-code diagram in Figure 3). The relative
movements of the two NBDs, is known to control channel gating,
hence the significance of this mode, or the alterations in mode 2
potentially caused by substitutions at the corresponding hinge
site.
These two results suggest that substitutions of amino acids (or
their side chains) at those particular regions could have an impact
on the collective dynamics of CFTR, and interfere with concerted
movements that would otherwise facilitate anion permeation. We
noted that the mean-square fluctuations in our model are minimal
at those particular residues (Figure S4), suggesting that mutations
at those sites could not be accommodated without affecting the
overall transporter structure and dynamics. Minimal mobility at
those mutation sites originates from the contribution of global
(most collective) modes. In contrast, the CFTRBD candidate
variants D1270 and S1235 are in close proximity on the surface of
the NBD2 (Figure 3), and had weaker functional effects than
other CFTRBD variants (Figure 1).
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Association of CFTRBD variants with sinus disorders and
male infertility
To examine the potential clinical relevance of CFTRBD
variants, we reviewed case report forms for additional CF
phenotypic features of dysfunction in the sinorespiratory and male
reproductive systems, which both use CFTR for bicarbonate
secretion. Association with CFTRCF alleles was used to test for
CFTR-mediated chloride secretion, CFTRBD to test for selective
bicarbonate-mediated secretion and, because both CFTRBD and
CFTRCF cause defective bicarbonate conductance, association
with either CFTRBD or CRTRCF alleles, or recessive genotypes
(CFTRBD/CRTRBD or CFTRCF/CRTRBD) to assess overall risk
of altered bicarbonate secretion on organ dysfunction.
The sinuses may use CFTR bicarbonate secretion, in part, for
mucus hydration [41]. Sinusitis is common, with a complex gene-
environment-anatomic risk that includes anatomy, allergies and
recurrent infections. Self-reported chronic sinusitis was more
common in pancreatitis cases (n = 151; 15.9%) than in controls
(n = 53; 10.2%, P = 0.002) (Table 2). We identified the R75Q,
R117H, L967S, L997F, D1152H, and S1235R CFTRBD variants
as well as CFTRCF-associated variants (e.g., F508del, G542X) in
cases with rhinosinusitis. Sinusitis was reported in pancreatic
cases who did not have any of the CFTR variants in our test
panel (p = 0.021; OR 1.51; CI 1.05-2.18), but risk increased
among carriers of CFTRBD (p = 0.001; OR 2.60, CI 1.43–4.60),
CFTRCF (p = 0.01; OR 2.47; CI 1.18–4.91) or either CFTRBD or
CFTRCF variant allele (p = 0.0001; OR 2.55; CI 1.55–4.15)
(Table 2). Rhinosinusitis was not statistically associated with
recessive genotypes, possibly due to the complex nature of
chronic sinusitis or requirement for an unidentified epistatic risk
factor.
CFTR bicarbonate secretion also plays a role in pH regulation
in the male reproductive system[42]. Male infertility is uncommon
and not dependent on recurrent infections. Self-reported male
infertility over age 30 years was more common among cases
(n = 17; 4.2%) than controls (n = 1; 0.4%, p = 0.03) (Table 2). We
identified R75Q, R117H, and S1235R as well as the CFTRCF
variants F508del, G542X and 2789+5G,A in male cases with
infertility. There was no increased risk of male infertility in cases
without CFTR variants (p = 0.28), but there was significant risk in
cases with either CFTRBD or CFTRCF alleles (p = 0.023; OR 10.7;
CI 1.03–536) or as a recessive genotype (p = 1.261027; OR 303;
CI 23–15783) (Table 2).
Discussion
Our integrative approach revealed a new functional class of rare
CFTR variants of clinical significance in pancreatic disease. Targeted
genotyping of reported and plausible CFTR variants in our cohort
identified candidate variants with a high pre-test probability of being
diseases associated, and these were evaluated for specific functional
studies in model cell types and focusing on a context-dependent
signaling pathway. Although the CFTRBD variants were scattered
throughout the genetic sequence, three-dimensional models of the
protein provided insight into structural and dynamic mechanisms of
dysfunction. Significant association between CFTRBD variants and
symptoms of sinusitis and male infertility, but not overt lung disease as
in CF, provided additional evidence of context-depended dysfunction
in humans. We believe that this type of integrated approach will be
important in understanding the genetic contribution to this and other
complex disorders and informing the development of therapeutics
that target the molecular etiology rather than the phenotype.
Table 2. CFTR variants in subjects with chronic rhinosinusitis or male infertility (age .30 years).
Rhinosinusitis Yes No p-value OR CI
Controls 53 (10.2%) 468 - - -
Cases (all) 151 (15.9%) 798 0.002 1.67 1.19–2.38
0 CFTRBD 111 649 0.021 1.51 1.05–2.18
0 CFTRCF 111 649 0.021 1.51 1.05–2.18
1 CFTRCF 14 50 0.011 2.47 1.18–4.91
1 CFTRBD 23 78 0.001 2.60 1.43–4.60
1 CFTRCF or 1 CFTRBD 37 128 0.0001 2.55 1.55–4.15
CFTRBD/CFTRBD or CFTRBD/CFTRCF 3 21 0.73 1.26 NS
Infertility Yes No p-value OR CI
Controls 1 (0.4%) 160 - - -
Cases (all) 17 (4.2%) 390 0.03 7.14 1.10–300
0 CFTRBD 8 329 0.28 3.88 0.5–174
0 CFTRCF 8 329 0.28 3.88 0.5–174
1 CFTRCF 2 24 0.051 13.0 0.65–786
1 CFTRBD 2 35 0.090 8.99 0.46–541
1 CFTRCF or 1 CFTRBD 4 59 0.023 10.7 1.03–536
CFTRBD/CFTRBD or CFTRBD/CFTRCF 5 2 1.20E-07 303 23–15783
Top: Chronic rhinosinusitis in NAPS2 controls and cases with 0, 1, or 2 CFTR mutations.
Bottom. Self-reported prevalence of male infertility among males over 30 years of age. Odds ratios were calculated comparing CFTR carrier cases in each subcategory
against all controls. Because CFTRCF and CFTRBD both affect bicarbonate conductance, we calculated the association and risk associated with the presence of either
variant type (shaded).
doi:10.1371/journal.pgen.1004376.t002
CFTR Bicarbonate Permeation Variants
PLOS Genetics | www.plosgenetics.org 6 July 2014 | Volume 10 | Issue 7 | e1004376
Figure 1. Functional characteristics of the nine CFTRBD variants. Panel a. Wild-type (WT) and variant CFTR proteins were expressed in HEK
293T cells and immunoblotted with anti-CFTR and anti-Aldolase antibodies. Replicate lanes are in small font. Band B, expected size of immature ER
core-glycosylated CFTR; band C, mature complex-glycosylated CFTR. Panel b. Whole-cell Cl2 currents were measured in WT and variant CFTR-
expressing HEK 293T cells, as described in Methods. Panel c. Whole-cell currents of WT-CFTR were measured in HEK 293T cells co-expressed with
WNK1 and SPAK using patch pipette contained a low concentration of Cl2 (10 mM). A representative trace of reversal potential measurement is
shown in the left panel. The permeability ratio PHCO3/PCl was calculated according to the Goldman-Hodgkin-Katz equation. I–V relationships at the
indicated points are presented in the accompanying graph. The conductance ratio GHCO3/GCl was calculated by measuring each outward current (i.e.,
slope between Erev and Erev+25 mV). RMP, resting membrane potential. Panel d. Whole-cell currents of R170H-CFTR were measured in HEK 293T cells
using the same protocol shown in panel c. Panel e. A summary of the PHCO3/PCl values obtained from WT-CFTR in the standard state (left) compared
to WT-CFTR and the nine CFTRBD variants with WNK1 + SPAK activation (right, underlined). Panel f. A summary of the GHCO3/GCl values in the standard
state (left) with WNK1 + SPAK activation (right). Values throughout are means 6 SEM. * p,0.05, **p,0.01: difference from WT in cells co-expressed
with WNK1 and SPAK.
doi:10.1371/journal.pgen.1004376.g001
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Evidence that CFTRBD variants are associated with
pancreatitis
One of the challenges of genetic association studies is
determining the effect of candidate genetic variants by statistical
tests when the variant is rare or the mutation effect is uncertain.
One approach is to increase study power by markedly increasing
study subject numbers, but this approach is prohibitively expensive
and not always feasible in rare diseases. Another approach is to
evaluate the combination of statistical trends linked to studies of
the functional effects of a variant in a biological system and a
biologically plausible framework.
In the current study, 11 variants that were previously reported
to be present in chronic pancreatitis but not CF causing
[16,17,43–52] underwent functional testing. Only CFTR
M470V and R1162 (not shown) did not meet criteria of altered
bicarbonate permeability and/or conductance after WNK1 and
SPAK activation (Figure 1e–f, discussed below). The remaining 9
CFTRBD variants were identified at least twice in pancreatitis
association studies over the past decade.
Five variants (R74Q, R75Q, R170H, L967S, and R1162L)
were located in the hinge region that modulates the collective
movements of the NBDs with respect to the MSDs (Figure 3).
R74Q was previously reported in a single chronic pancreatitis
patient [53] but not in the CFTR2 database. CFTR R74Q was
identified by us in two cases and no controls (p = ns) and in one
case who was a SPINK1 N34S carrier (p = 0.006). R75Q is
considered to be a non-CF causing mutation according to the
CFTR2 mutation database [54]. CFTR R75Q was identified in
61/906 cases and 75/1214 controls (6.3 vs. 6.2%, p = ns) but was
also detected in nine SPINK1 N34S/- mutation carriers (9/55,
16.4%), with strong combined effect (SPINK1 OR 3.7, SPINK1+
R75Q compound OR 12.2, p 0.002). Two of the nine trans-
heterozygous cases had been previously reported[18]. R75Q was
also identified in four cases with a concurrent severe CF-causing
mutation and in no compound controls. R170H was first reported
Figure 3. Location of selected variant sites with respect to the collective modes of the CFTR. The left panel displays the relative motions
of individual residues along the collective modes 1 (top) and 2 (bottom) intrinsically accessible to the two transporter subunits (residues 71–645 and
846–1445, respectively). These modes divide the CFTR structure into two groups of residues (colored red and blue in the ribbon diagrams) subject to
opposite-direction motions. The pale blue/pink indicate the central locations (or hinge regions) mediating the concerted anti-correlated movements
of the two groups. L967, D1152 and R1162 participate in the hinge region that modulates the concerted anti-correlated (opening/closing)
movements of the two membrane-spanning domains in mode 2. Residues indicated by filled points (left curves) or yellow spheres (right diagrams) are
R74, R75, R117, R170, L967, L997, D1152, R1162, S1235 and D1270.
doi:10.1371/journal.pgen.1004376.g003
Figure 2. Molecular modeling and simulations of CFTR WT and variants. Panels a and b display the side and bottom views, respectively, of
the WT CFTR dimer, where the two nucleotide-binding domains and the two membrane-spanning domains are labeled as NBD and MSD. The shaded
region indicates the location of the lipid bilayer. Color key: black, subunit 1 of CFTR, with residues 1–859; blue, subunit 2, residues 860–1480; red
CFTR variants studied. Panel c shows the charge distribution around D1152H: this negatively charged residue (left; shown in red space-filling
representation) is surrounded by several positively charged residues (green), especially on its side of the cavity, creating an attractive force that keeps
the residue from extending into the cavity. Also shown are other negatively charged residues (red stick or space-filling representation), including
D385, diametrically opposite to D1152. Panel d shows the corresponding scene for the variant residue, D1152H (cyan), which can move toward the
center of the cavity, thus leading to a constriction in the channel diameter. Channel diameter at the location of variant residues: Panel e
shows the diameter of the channel at the location of L997, as a function of time, both for the WT (L997, green curve) and the variant (F997, red curve),
based on closest interatomic distance between L997/F997 and D385. On panel f, the same information for the WT and variant D1152H is shown. In
both plots, the pore diameter in the WT is larger than that stabilized in the mutants. The histograms of channel sizes are shown along the right
ordinate.
doi:10.1371/journal.pgen.1004376.g002
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in two cases of congenital bilateral aplasia of vas deferens in
England [53] but is not currently in the CFTR2 mutation
database. CFTR R170H was identified in three cases and no
controls (p = ns). L967S has been reported in a single case of
azoospermia from the CF mutation database [53] but is not in the
CFTR2 mutation database. L967S was identified in ten cases (one
trans-heterozygote), two controls (OR 6.9 p = 0.004), and one
N34S case carrier. R1162L is predicted to be a highly deleterious
variant by SIFT and damaging by PolyPhen modeling [55] and is
included in the CFTR2 mutation database and classified as a
variant not causing CF. Although located in a critical portion of
the CFTR molecule, the association and functional threshold for
inclusion as a CFTRBD variant were not fully met.
Two variants (L997F and D1152H) appeared to reduce channel
diameter. L997F is considered a mutation of varying clinical
consequences for CF, with low rates of pancreatic insufficiency
and retention of chloride conductance [54]. In this study L997F
was identified both in the cases (0.7%) and controls (1.0%),
additionally, L997F was identified in one N34S case carrier and
three compound heterozygous mutation case carriers, but
independent statistical association with pancreatitis was not
demonstrated in this study. D1152H is a mutation of varying
clinical consequence for CF and is associated with low rates of
pancreatic insufficiency and retention of chloride conductance
[53]. CFTR D1152H was identified in four cases and no controls
(p = 0.014). Two of these cases were in compound heterozygosity
with F508del.
Two variants (S1235 and D1270N) were on the surface of
NBD2 (Figure 2). S1235 is a non-CF-causing mutation[54] and
was identified in 2.4% of cases and 1.4% of control (p = ns), three
compound heterozygous cases and one N34S case carrier. While
this did not reach statistical significance in this cohort, multiple
previous reports of CFTR S1235R in idiopathic pancreatitis
patients[56,57] and complex functional features [27] were noted.
D1270N is of varying clinical consequences for CF, with low rates
of pancreatic insufficiency and retention of chloride conductance
[54]. D1270N was identified both in the cases (0.3%) and controls
(0.2%). Although these variants have been identified in previous
studies, the effects of these rare variants on altered bicarbonate
permeability and conductance appear to be weak (Figure 1 e–f)
and the effect on the function of NBD2 (Figures 2–3) is unclear.
However, they meet minimal criteria for the class on function
grounds and contribute to the overall effect on disease risk.
The final variant (R117H) is located in an extracellular domain
and has functional effects beyond the other CFTRBD variants.
R117H is a complex variant that is associated with CF only when
found in cis with a T5 tract in intron 8. The CFTR R117H variant
was identified in 22 cases (2.3%) and 8 controls (0.7%) (p = 0.001),
with only 3 cases and 1 control having the CF-associated
R117H*T5 haplotype (p = ns), which links the CFTR variant
R117H to pancreatitis regardless of the intron 8 T5 haplotype.
R117H*T7/T9 was also identified in 9 of the 80 cases with a
concurrent severe CF-causing mutation and in no CF carrier
controls. The R117H variant was the only one with reduced
chloride current density (Figure 1b). While the variant was
associated with altered bicarbonate permeability and conductance,
the mechanism is yet to be determined.
Common CFTR variants previously associated with
pancreatitis but not confirmed in the current study
The common polymorphisms M470V, T854T, and Q1463Q
had no significant association with pancreatitis, either individually
or combined in haplotypes, in contrast to a previous report [58].
Haplotypes were determined by counting homozygous carriers of
each subset (M470V, T854T, P1290P, Q1463Q and M470V,
IVS-T, IVS-TG) and applying Fisher’s exact test. The IVS8 T/
TG/M470V allele was evaluated in 784 NAPS subjects and
controls, and no significant associations were found, in contrast to
another report[59]. The possibility that a series of complex
haplotypes affect CFTR expression or exon skipping was not
excluded, but no evidence of direct association was seen in the
current study or our previous pancreatitis GWAS [24].
Thirty-seven of the 81 CFTR variants tested were not
identified in any cases among the NAPS2 cohort. The remaining
variants were also not significantly overrepresented alone or with
SPINK1 or CF mutation carrier. I148T was seen in three cases
and one control, so an effect could not be detected or excluded;
the in cis deletion mutation 3199del6 was not detected in any
I148T carriers. The IVS8T5 variant was identified in 9.9% of
cases and 8.2% of controls, which is not individually significant.
There were six N34S/T5 trans-heterozygote controls and no
cases, but the combined odds ratio (OR 3.9) of the SPINK1
N34S variant with IVS8T5 was not significantly higher than
N34S alone. Four additional variants were identified in only one
patient and no controls: CF mutations 2184delA, 3120+1G.A,
R1162X and a mutation of varying clinical consequence,
G1069R.
Taken together, these genotyping and functional studies provide
strong rationale for inclusion of nine variants as CFTRBD class
members. Although additional variants may be added to the
CFTRBD class in the future, the current study did not have the
very large patient size needed to provide adequate power to detect
statistically significant changes in additional rare variants. In
addition, other possible mechanisms of CFTR channel dysfunction
linked to altered bicarbonate conductance are possible, such as
mechanisms linked to CFTR R117H.
Structural significance of CFTRBD mutants
Structure-based simulations can provide insights into molecular
driving forces and thereby into the mechanisms of channel
dysfunction. To better understand the location and structural
effects of the nine amino acid variants conferring risk of
pancreatitis and causing dysfunction of the electrophysiological
response to WNK1-SPAK activation, we developed structural
models of CFTR and conducted dynamic simulations. Because no
crystallographic structures for the entire human CFTR are
currently available, we built a homology model based on the
structure of a bacterial ABC transporter (Sav1866) from Staph-
ylococcus Aureus [35]. Several computational studies have been
carried out using models of CFTR and other ABC transporters
that focus on the structure and/or gating cycle of the molecule
and the effect of common mutations/deletions (e.g., F508del in
CFTR) [4,5,35–37,39,60–64]. Our study is, to our knowledge,
the first to investigate the multiscale dynamics of CFTR by
examining both the global motions of the overall protein (with
ENM) and the local effects of particular CFTRBD variants (with
MD). The ENM analysis highlighted the critical positioning of
R74, R75, R170, L967, and R1162 at the global hinge regions
(those between the NBD and MSD of transporter in mode 1, and
between the two NBDs in mode 2), as evidenced by the
significant suppression of residue fluctuations in their close
neighborhood. Mutations at those sites would thus be expected
to interfere with the functional dynamics of the channel. Our all-
atom MD study, on the other hand, showed that a substantial
constriction could arise in channel diameter with substitutions at
residues lining the wall of the channel. In particular, the L997F
and D1152H mutants showed channel pore size reductions in
CFTR Bicarbonate Permeation Variants
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their neighborhoods that would directly affect conductance
properties.
Defects in CFTR bicarbonate transport
The fact that all of the pancreatitis-associated variants identified
by genetic screening in this study resulted in defective WNK1-
SPAK-activted increase in bicarbonate secretion supports the
argument that this mechanism is critical for bicarbonate-secreting
cells that utilize CFTR as the primary anion channel. The
importance of bicarbonate conductance across CFTR at the apical
membrane is magnified if chloride, but not bicarbonate, conduc-
tance across the basolateral membrane is minimal, as predicted for
the pancreatic duct cell [6], since the transcellular anion
conductance is responsible for fluid secretion. Under basal
conditions, CFTR-mediated bicarbonate permeability is only
,20% of chloride, and the capacity for facilitating high
bicarbonate flux for bicarbonate-secreting tissues is limited. Under
conditions of low-intracellular chloride, the WNK1-SPAK path-
way are activated, and this in turn transforms CFTR into a highly
bicarbonate-permeable anion channel (Figure 1). The molecular
mechanisms as to how WNK1-SPAK increases the CFTR
bicarbonate permeability remain unclear. However, increasing
evidence suggests that ion permeability of anion channels is not
fixed and can be dynamically modulated by cellular signaling and
other events [65].
The pore of anion channels is believed to have a large
polarizable tunnel, where ion selectivity is basically determined by
the hydration energy of ions and polarizability of the channel pore
[65]. Therefore, in general, the CFTR ion channel is more
permeable to large anions that are more readily dehydrated [66].
However, this cannot be applied to HCO3
2. Although the size of
HCO3
2 (equivalent radius: 2.1 or 2.43 A˚) is larger than Cl2
(1.81 A˚), most anion channels, including CFTR, exhibit poor
HCO3
2 permeability because of the asymmetrical charge
distribution of HCO3
2 [67]. A decrease in the CFTR pore
diameter, as shown in L997F, can affect the permeability of
HCO3
2 in many ways, such as by limiting the accessibility of
large, asymmetrically charged HCO3
2 to the channel pore. A
second mechanism of reducing HCO3
2 permeability and
conductance is to inhibit the interaction between CFTR and
WNK1/SPAK or to reduce the WNK1/SPAK-mediated confor-
mational change of CFTR. The elucidation of precise molecular
mechanisms of each mutation will provide insights into the
understanding of HCO3
2 conduction in CFTR and also in other
anion channels.
Conclusion
Taken together, these findings support a new class of CFTR
functional variants with a specific defect in responding to WNK1-
SPAK activation with increased bicarbonate permeability –
conductance, dubbed CFTRBD. As a class, these nine variants are
more common in pancreatitis cases than in controls and also had
evidence of significant risk of pathology in other organs utilizing
CFTR for bicarbonate secretion. New insight into multiple
plausible mechanisms were gained by developing a structural
model of the entire CFTR molecule and by analyzing the
collective dynamics for wild type and disease-causing variants
that result in altered channel function. Together, these findings
provide new understanding of the complexity of pancreatic
disease related to CFTR-associated duct dysfunction. Identifica-
tion of members of this new class of CFTR variants on DNA
sequencing of symptomatic patients in whom a bicarbonate
channelopathy is suspected may provide insight into disease
mechanisms and guidance for patient-specific clinical manage-
ment decisions.
Materials and Methods
Study cohort
The NAPS2 cohort was ascertained, and data were collected as
described previously [23]. All patients were prospectively enrolled
using protocols approved by the appropriate IRBs. Physician-
confirmed diagnosis of pancreatitis was required for enrollment as
a case, while questions on CF, chronic sinusitis, and male infertility
were included on a case report form administered by a clinical
research coordinator. DNA and phenotypic data for patients with
chronic and recurrent acute pancreatitis (n = 984) and healthy
unrelated controls (n = 467 from the NAPS2 case-control study
[23,68] plus DNA from additional healthy controls from
SomaLogic Inc. (Boulder, CO) (n = 377), the Inflammatory Bowel
Disease Genetics Consortium (Dr Richard Duerr, University of
Pittsburgh) (n = 338) and additional University of Pittsburgh
studies of pancreatitis and pancreatic cancer (Drs David
Whitcomb and Randall Brand, University of Pittsburgh) (n = 42)
[24] were evaluated for a final study cohort of 984 cases and 1224
unrelated controls.
Genotyping
PRSS1 genotyping was done by DNA sequencing [69].
SPINK1 genotyping was done by sequencing exons 2–3 and the
flanking regions in a preliminary subset of 745 NAPS2 cases, with
the entire cohort (cases and controls) genotyped for p.N34S,
p.P55S and c.27delC using TaqMan assays. The SPINK1 c.194+
5G.A variant [70] was seen in one patient and one control;
c.194+2T.C [71] was not identified in the initial sequencing and
was not further genotyped.
CFTR variants for the screening panel were selected from a
review of published papers and abstracts between 1998 and 2010
[16,17,43–52] and the open access CFTR mutation database
based in the Hospital for Sick Children in Toronto (http://www.
genet.sickkids.on.ca) and Johns Hopkins University (Http://
CFTR2.org).
CFTR genotyping was done using a custom MassARRAY
iPLEX Gold assay (Sequenom, Inc, San Diego, CA) or custom
TaqMan Gene Expression Assays (Life Technologies Corporation,
Carlsbad, CA) through the Genomic and Proteomic Core
Laboratories at the University of Pittsburgh and verified by
bidirectional DNA sequencing. All cases and controls were tested
for each of the 81 selected CFTR variants (Table S1). Variants
were selected in three stages: the most common CF-causing
mutations in North America, variations that have been reported in
pancreatitis literature at least once and a subset of variants that
have been reported in CF patients but for which the biological and
pathological relevance remains undetermined (Mutations of
Undetermined Clinical Significance). 67 SNPs (125GtoC,
1716G.A, 1717-1G.A, 1898+1G.A, 2183AA.G, 2184delA,
2789+5G.A, 3120+1G.A, 3659delC, 3849+10kbC.T, 621+
1G.T, 711+5G.A, A455E, D110H, D1152H, D1270N, D443Y,
D579G, F1052V, F1074L, F508C, F508del, G1069R, G1244E,
G1349D, G178R, G542X, G551D, G551S, I1131L/V, I148T,
I336K/T, I507del, I807M, IVS8T5, K1180T, L1065P, L967S,
L997F, M1V, M470V, M952I, M952T, N1303K, P67L,
Q1463Q, R1070Q, R1162X, R117C, R117H, R170H, R258G,
R297Q, R31C, R352Q, R553X, R668C, R74W, R75Q, S1235R,
S1255P, S485R, S977F, T338I, T854T, V201M, W1282X) were
multiplexed into 6 wells; 14 SNPs (S492F, S945L, R74Q, R560T,
R1162L, G85E, I1027T, R334W, R347P, G576A, 711+1G.T,
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1001+11C.T, P1290P, 3199del6) were ascertained separately via
TaqMan Gene Expression Assays, with repeat confirmation of all
positive results. 3199del6 was genotyped via TaqMan on all
samples that tested positive for I148T. In addition, the intron 8
boundary was directly sequenced in 873 subjects to determine the
significance of the IVS8 T/TG tract.
Statistical analysis
Significant differences in carrier frequencies among cases and
unrelated controls were determined by chi square analysis or
Fisher’s exact test, and two-tailed p-values are reported. The
results of each set of experiments are presented as means 6 SEM.
Statistical analysis was performed using Student’s t-tests or analysis
of variance followed by Tukey’s multiple comparison test as
appropriate. P,0.05 was considered statistically significant.
Cell culture and plasmids
HEK 293T cells were maintained in Dulbecco’s modified
Eagle’s medium-HG (Invitrogen, Grand Island, NY) supplement-
ed with 10% fetal bovine serum, 100 U/ml penicillin, and
0.1 mg/ml streptomycin. The mammalian expressible plasmids
for hCFTR[72], Myc-rWNK1[21] and Flag-mSPAK [20] were
described previously. Plasmids were transiently transfected into
cells using Lipofectamine 2000 reagents (Invitrogen, Grand Island,
NY). An average transfection rate over 90% was confirmed by
transfection with a plasmid expressing green fluorescence protein
(pEGFP-N1). Plasmids expressing variant hCFTRs were generated
using a PCR-based site-directed mutagenesis kit (Stratagene, Santa
Clara, CA).
Immunoblotting
Immunoblotting was performed using conventional methods
[20]. Briefly, cells were harvested with lysis buffer (20 mM HEPES
pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 1 mM
NaVO4, and 1 mM b-glycerophosphate) containing a complete
protease inhibitor mixture (Roche Applied Science, Mannheim,
Germany). Protein samples were suspended in a sodium dodecyl
sulfate buffer and separated by SDS-polyacrylamide gel electro-
phoresis. The separated proteins were transferred to a nitrocellu-
lose membrane and blotted with appropriate primary and
secondary antibodies, and protein bands were detected with
enhanced chemiluminescence solutions. Antibodies against CFTR
(M3A7, Millipore, Billerica, MA) and aldolase A (N-15, Santa
Cruz Biotechnology, Inc., Dallas, TX) were obtained from
commercial sources.
Electrophysiology
Voltage and current clamp experiments were performed on
HEK 293T cells transiently transfected with hCFTR as previously
reported with slight modifications [20]. Briefly, cells were
transferred into the bath mounted on a stage with an inverted
microscope (IX-71, Olympus, Osaka, Japan). The pipettes were
pulled by a Sutter P-57 puller and have free-tip resistances of
about 2,5 MV. These were connected to the head stage of a
patch-clamp amplifier (Axopatch-700B, Molecular Devices, Sun-
nyvale, CA). Ag-AgCl reference electrodes were connected to the
bath via a 1.5% agar bridge containing 3 M KCl. Liquid junction
potentials were corrected for each experimental solution as
described previously[20]. For the anion permeability test, individ-
ual data were corrected by measuring the offset potential shift
induced by the replacement of anion solution after each
experiment. The conventional whole-cell clamp was achieved by
rupturing the patch membrane after forming a gigaseal. Voltage
and current traces were stored and analyzed using Clampfit v.10.2
(Molecular Devices, Sunnyvale, CA). Currents were sampled at
5 kHz. All data were low-pass filtered at 1 kHz.
The high-chloride pipette solution contained (mM) N-methyl D-
glucamine chloride (NMGD-Cl), 5 ethylene glycol tetraacetic acid,
1 MgCl2, 3 Mg-ATP and 10 4-(2-hydroxyethyl)-1-piperazineetha-
nesulfonic acid (HEPES)(pH 7.2). The low-chloride pipette
solution was prepared by replacing Cl2 with equimolar glutamate.
The stand bath solution contained (mM) 146 NMDG-Cl, 1 CaCl2, 1
MgCl2, 10 glucose and 10 HEPES (pH 7.4). The high-bicarbonate-
containing bath solution was made by replacing NMDG-Cl with
equimolar choline-HCO3. The bicarbonate-containing solution was
continuously gassed with 95% O2+5% CO2.
In all experiments, currents generated by CFTR were
confirmed by the following three characteristics: 1) activation of
current by the treatment with cAMP (5 mM forskolin and 100 mM
1-methyl-3-(2-methylpropyl)-7H-purine-2,6-dione (IBMX), 2) a
linear I–V relationship and 3) inhibition of current by the
treatment with the CFTR inhibitor CFTRinh-172.
The current reversal potential (Erev) was measured either in
current clamp mode or in voltage clamp experiments. Resting
membrane potential (RMP) was recorded in zero current clamp
mode. To test the current-voltage relationship during zero-current
clamp recording, clamp mode was shifted to the voltage clamp
mode, and the I–V curve was achieved with ramp pulses from -
100 to 100 mV (250 ms, holding potential; near the RMP). All
currents were corrected for capacitative currents and the I–V
relationship was plotted using the values of current density (pA/
pF). The relative anion permeability was determined by the
reversal potential shift (DErev = Erev(X) – Erev(Cl)) induced by
replacing extracellular Cl2 with X2 anion using the Goldman-
Hodgkin-Katz equation as follows: PX/PCl = exp(DErev/(RT/zF)
– ([Cl2]o/[Cl
2]’o))6 ([Cl
2]’o/[X
2]o), where [Cl
2]’o is the bath
concentration of Cl2; [Cl2]o is the residual Cl
2 in the substituted
solution; [X2]o is the concentration of substitute ion; and R, T, z
and F have their conventional thermodynamic meanings. The
anion outward chord conductance (GX: X is anion) between Erev
and Erev +25 mV was achieved by linear plotting.
Structural modeling
The homology model of human CFTR (UniProt accession
code: P13569) was obtained using the Swiss-Model Workspace
software [73]. The most recently resolved crystal structure of the
Staphylococcus Aureus sav1866 ABC transporter, fitted to the
human CFTR (PDB code: 4A82, 2.0 A˚ resolution) [36] was
adopted as a template, and the structural model was completed
using the X-ray crystallographic structure of the NMD2 region of
human CFTR (PDB code: 3GD7, resolution 2.7 A˚) (see Figure
S3a). This model deviates from the template structure by 1.6 A˚
RMSD, and in our simulations the RMSD levels off at ,3.5 A˚.
The MSD pore-lining residues and pore radius profile (Figure
S3b–c) were consistent with those observed in a homology model
constructed by Norimatsu and coworkers [37,39], which was
based on an earlier structure (PDB code: 2HYD, resolution 3 A˚)
[35]. Using this model for WT CFTR, we generated in silico
models for the mutants L997F and D1152H.
Of note, the collective modes predicted by ANM are highly
robust and they are not sensitive to small structural variations (like
those due to a different model).
Molecular dynamics simulations and elastic network
model analysis
Molecular dynamics simulations were performed using the
AMBER11[74] package (GPU version of the pmemd program),
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with the Amber99SB[75] force field and using the TIP3P water
model. The protocol consisted of an initial minimization in
vacuum, using 1,500 steepest descent and 1,500 conjugate
gradient steps, to remove strong steric contacts, followed by
another minimization of 5,000 steepest descent and 5,000
conjugate gradient steps, in explicit solvent, followed by a
production run of 50 ns. The systems were kept at a temperature
of 300 K, using Langevin dynamics with a collision frequency of
2 ps21; the SHAKE algorithm was adopted to use a 2 fs time step.
The stability of the system was assessed by verifying the
convergence of the root mean square deviation (rmds) of its heavy
atoms, after the first 5 ns of simulation.
As to the pore regions where we examined the local effects of
substitutions, we allowed for the relaxation and optimization of
interactions during the described protocol. The simulations,
thus, gave rise to local rearrangements in the neighborhood of
the mutation sites and permitted us to extract statistical data on
the average pore diameter at the constriction zone and its
fluctuations.
The elastic network model analysis of collective dynamics was
performed using the approach reviewed earlier[40]. Collective
modes of motions are evaluated by eigenvalue decomposition of
the connectivity/Hessian matrix, using the Gaussian/Anisotropic
network model. The shape of the mode permits us to identify
regions subject to large fluctuations as well as domains undergoing
anti-correlated movements (colored blue and red in the ribbon
diagrams, Figure 3).
Ionic diameter
The radii of the mono-atomic chloride ion was taken from
Bondi [34]. The equilibrium geometry of bicarbonate ion was
optimized using ab initio quantum mechanics at DFT level, with
the B3LYP/6-311G** basis set, via the Gaussian 03 software. This
resulted in a bicarbonate ion that could be fit in a minimum box of
size 3.40 A˚64.86 A˚65.39 A˚. This yields a van der Waals radius of
2.1 (or 2.43) A˚ for the bicarbonate ion, based on the two smaller
dimensions (or the second largest dimension) that define the
minimal cross-sectional area.
Unless specified otherwise, when we refer to the diameter of the
pore, we mean the minimal diameter at the specific location of the
mutation, as opposed to the distribution of diameters along the
pore.
Supporting Information
Figure S1 Measurement of PHCO3/PCl in cells without WNK1
and SPAK co-expression. Control experiments were performed.
Whole-cell recordings were performed to measure CFTR
bicarbonate permeability by replacing the bath solution with high
HCO3
–-containing (140 mM) solution. Cells were stimulated with
cAMP (5 mM forskolin and 100 mM IBMX) after establishing
whole-cell configuration. The current to voltage relationship (I/V
curve) was obtained by depolarizing ramp pulses from 2100 to +
100 mV. The permeability ratio PHCO3/PCl was calculated
according to the Goldman-Hodgkin-Katz equation. I–V relation-
ships at the indicated points are presented in the right panel. The
conductance ratio GHCO3/GCl was calculated by measuring each
outward current (slope between Erev and Erev+25 mV). Replacing
the bath solution with a high-bicarbonate-containing solution
induced a strong positive shift in Erev, indicating that bicarbonate
permeability is much smaller than that of chloride. Summarized
results of multiple experiments (n = 7) are presented in Figure 1e
and f.
(PDF)
Figure S2 Representative current to voltage (I–V) plots of CFTR
variants in whole-cell current measurements. Whole-cell record-
ings were performed to measure the CFTR HCO3
- permeability
and conductance by replacing the bath solution with high HCO3
–-
containing (140 mM) solution. The pipette solution contained
10 mM Cl-. WNK1 and SPAK kinases were coexpressed with
wild-type (WT) or variant CFTR. Cells were stimulated with
cAMP (5 mM forskolin and 100 mM IBMX) after establishing
whole-cell configuration. The I–V curve was obtained by
depolarizing ramp pulses from 2100 to +100 mV (250 ms), and
all currents were corrected for capacitative currents. Treatment
with the CFTR inhibitor CFTRinh-172 (20 mM) inhibited the
HCO3
- currents by an average of 91.863.0% (WT-CFTR with
WNK1 & SPAK coexpression, measured at +100 mV, n = 4)
indicating that CFTR mediates most of the HCO3
- currents. The
permeability ratio PHCO3/PCl was calculated according to the
Goldman-Hodgkin-Katz equation. The conductance ratio
GHCO3/GCl was calculated by measuring each outward current
(slope between Erev and Erev+25 mV).
(PDF)
Figure S3 Structural features of the present homology model
and comparison with previous work. Panel a shows the
superposition of the current homology model onto the X-ray
structure of ABC transporter from S. aureus, which yields an
RMSD of 1.6 A˚. Panel b shows the position of some residues
lining the pore at the MSD, located on two TM helices, 6 (red) and
12 (yellow). These residues were reported by Sansom and
collaborators to be lining the MSD pore [61], based on both, a
homology model and experimental cysteine scanning. Panel c
shows the MSD pore radius profile—measured as the radius of the
smallest circle that fits the cross sectional area at each elevation
along the pore axis (perpendicular to the membrane plane), and its
extension toward the cytoplasmic region. The MSD portion
(indicated by the upper abscissa label) is comparable to that
reported earlier by Norimatsu et al [37].
(TIFF)
Figure S4 Contribution of the slowest modes to the square
displacements of residues in CFTR. Square displacements are
calculated using the ENM representation of the two subunits of the
structure (residues 71–645 and 846–1445, respectively). The right
panel shows a color-coded ribbon diagram where regions subject
to large fluctuations are colored pink, and those maximally
constrained, blue. Note that R74, R75, R170, L967, D1152 and
R1162 lie in the highly constrained region.
(TIF)
Table S1 81 CFTR variants genotyped in pancreatitis patients.
The CFTR mutations investigated in this study are reported with
legacy nomenclature and relative ranking among the American
College of Medical Genetics most common classic cystic fibrosis-
causing mutations found in North America (CF). Those found to
be associated with cases in the current cohort include an X in the
Panc Disease column. *IVS8 T5 and R117H are reported but CF
disease causing only when in cis with each other or IVS8 T5 with
IVS8 TG12or13. Intronic mutations are reported in standard
nomenclature ‘‘####+/2##N.N’’ except IVS8-T5, (1210-
12T[5]).
(DOCX)
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